胃癌的生物化疗
摘要
胃癌（Gastric carcinoma）具有明显的地域性，尤其是东亚三国（日本、韩国和中国）为高发区，约占全球总数的2／3，近年来发病率略呈下降趋势。可是在我国，胃癌仍高居各种恶性肿瘤之首。
出处
《肿瘤预防与治疗》
2009年第4期443-446,共4页
Journal of Cancer Control And Treatment
参考文献18
-
1van Custem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group [ J] . J Clin Oncol, 2006, 24(31) : 4991-4997.
-
2Cunnihgham D, Ran S, Starling N, et al. Randomized multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced esophagogastric cancer. The REAL-2 trial[J]. J Clin Oncol, 2006, 24: 18s ( abstr 4017 ) .
-
3Dank M, Zaluski J, Barone C, et al. Randomized phase III trial of irinotecan (CPT-11) +5-Fu/folinic acid (FA) vs CDDP + 5-FU in 1st-line advanced gastric cancer patients [J]. J Clin Oncol, 2005, 23: 16s( abstr 4003) .
-
4Narahara H, Koizumi W, Hara T, et al. Randomized phase III study of S- 1 alone versus S- 1 + cisplatin in the treatment for advanced gastric cancer ( The SPIRITS trial) . SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer [ J] . J Clin Oncol, 2007, 25 : 18s( abstr 4514).
-
5Kang Y, Kand WK, Shin DB, et al. Randomized phase IlI trial of capecitabine/cisplatin (XP) vs continuous infusion of 5-Fu/cisplatin (FP) as first-line therapy in patients with advanced gastric cancer (AGC) , efficacy and safety results [J] . J Clin Oncol, 2006, 24: 18s( abstr 4018) .
-
6Boku N, Yamamoto S, Shirao K, et al. Randomized phase III study of 5-Fluorouracil (5-Fu) alone versus combination of Irinotecan and Cisplatin (CP) versus S-I alone in advanced gastric cancer( JCOG 9912) . ASCO Annual Meeting Proceedings, Part II [ J] . J Clin Oncol, 2007, 25 : 18s ( abstr 4513 ).
-
7Ajani J A, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S- 1 (CS) with eisplatin/5-Fu (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS) [ J/OL]. J Clin Oncol, 2009 : ( abstr 8).
-
8Tebbutt N C, Sourjina T, Striekland A H, et al. ATTAX2: Doeetaxel plus cetuxlmab as second-line treatment for doeetaxel-refraetory esophago-gastric cancer: final results of a muhieentre phase II trial by the AGITG[ J/OL]. (2008 ASCO Annual Meeting Proceedings). J Clin Oneol. 2008.26 :15554.
-
9Rojas Llimpe F L, Di Fabio F, Ceccarelli C, et al. Prognostic signifieanee of ki67, p53, TS and EGFR in advanced gastric and gastroesophageal junction cancer patients treated with cetuximab plus FOLFIRI (FOLCETUX study) [ J/OL]. (2007 ASCO Annual Meeting Proceedings). J Clin Oncol, 2007,25 : 4604.
-
10Han S, Park S R, Lee K, et al. Phase II study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer[ J/OL]. (2008 ASCO Annual Meeting Proceedings). J Clin Oncol. (Meeting Abstraots), 2008, 26: 45-49.
-
1王金万.胃癌[J].癌症进展,2004,2(2). 被引量：6
-
2王梅,顾军,沈晓莹,李咏梅,王薇,王雅杰.中国上海地区乳腺癌的临床病理特征分析[J].临床肿瘤学杂志,2012,17(5):437-441. 被引量：1
-
3宋恕平,盛立军,任国华.前列腺癌的诊治进展[J].中国处方药,2008(6):80-81. 被引量：2
-
4李奕.前列腺癌病理学诊断的概况[J].辽宁医学杂志,2008,22(5):251-256. 被引量：2
-
5李健,谢冬玲,王立东.内镜技术在食管癌诊断中的应用[J].世界肿瘤杂志,2004,3(1):1-4.
-
6张庆慧,陈玲,顾金花,刘芸,段厚全,俞黎亚.血清中幽门螺杆菌CagA抗体在东亚三国胃癌诊断中作用的meta分析[J].同济大学学报（医学版）,2012,33(5):105-109. 被引量：2
-
7王薇,付肖岩.391例胃癌发病特征及内镜病理分析[J].国际消化病杂志,2010,30(1):56-57. 被引量：3
-
8王琳,秦叔逵.口服氟尿嘧啶类制剂治疗进展期胃癌的新进展[J].中国处方药,2009(1):62-65. 被引量：8
-
9朱展芳.如何自查甲状腺[J].健康必读,2011(12):57-57.
-
10胡堃,马明.食管癌基因方面的新知识[J].癌症康复,2014,0(3):88-88.
